Omkar Speciality Chemicals Limited has disclosed the outcome of its Monitoring Committee meeting held on April 15, 2026, which detailed significant capital restructuring steps. The committee approved a record date for the total cancellation of existing promoter and public equity shares and authorized the private placement of 5,000,000 new equity shares to a specific strategic investor. Additionally, the company announced the appointments of Mr. Mahendra Kumar Jain as Chief Financial Officer and Mr. Kuldeep Menaria as Company Secretary to lead its management team.

The meeting served to implement the Resolution Plan approved by the NCLT Mumbai bench on July 31, 2025, following the company’s admission into the Corporate Insolvency Resolution Process (CIRP) in late 2022. Key actions include fixing April 29, 2026, as the record date for the extinguishment of all existing promoter and public shares. To recapitalize the firm, 50,00,000 new equity shares will be issued at a face value of INR 10 each, totaling INR 5 Crores, to IFFAS Kshitij SPV LLP. The committee also approved a loan of up to INR 20 Crores from Kshitij Polyline Limited and integrated a previous earnest money deposit of INR 21.90 Crores into the resolution plan’s debt structure.

Omkar Speciality Chemicals Limited is an Indian-based manufacturer specializing in a diverse range of organic, inorganic, and organo-inorganic intermediates. Its product portfolio includes iodine derivatives, bismuth salts, selenium compounds, and pharmaceutical intermediates, primarily serving the pharmaceutical, glass, and cosmetic industries. In 2025, the company’s trajectory was defined by the legal transition through the insolvency process, culminating in the NCLT’s approval of its Resolution Plan in July 2025 to restore operational stability.

Financial results for the company have been under significant pressure, with the organization being managed by a Monitoring Committee rather than a traditional board during the CIRP. In 2025, the company continued to report poor sales growth, with recent historical data showing a five-year sales decline of approximately 40.8%. As of April 2026, the promoter holding stood at 14.71%, while retail investors held the vast majority of shares at 85.22%. There are currently no “superstar” or famous individual institutional investors listed in the 2025-2026 shareholding records, reflecting its status as a small-cap firm undergoing restructuring.